What is the main purpose of this 8-K filing by Gilead Sciences?

The main purpose of this 8-K filing is to formally announce Gilead Sciences' financial results for the second quarter ended June 30, 2022, and to provide investors with access to the detailed press release containing these results.

Where can I find the detailed financial results for Q2 2022?

The detailed financial results, including operational highlights and segment performance, are available in the press release filed as Exhibit 99.1 to this 8-K report.

What is the difference between GAAP and non-GAAP financial information presented by Gilead?

GAAP (Generally Accepted Accounting Principles) are standard accounting rules. Non-GAAP financial information is a supplemental measure used by Gilead's management for internal operational, budgeting, and financial planning purposes. While management believes it's useful, it's not prepared under comprehensive accounting rules and may differ from how other companies present non-GAAP data. Investors should use non-GAAP information to supplement their understanding of GAAP results, and a reconciliation is provided in the press release.

Does this filing contain any new business initiatives or significant corporate changes?

This specific 8-K filing is primarily focused on reporting the company's quarterly financial results. It does not explicitly detail new business initiatives or significant corporate changes, which would typically be found in other sections of an 8-K or separate press releases. For such information, investors should refer to the content of the accompanying press release (Exhibit 99.1) and other Gilead filings.

GILD 8-K: Earnings & Results

Summary

Gilead Sciences, Inc. (GILD) has filed an 8-K report on August 2, 2022, to announce its financial results for the second quarter ended June 30, 2022. The report primarily refers to a press release (Exhibit 99.1) which contains the detailed financial performance and operational highlights for the period. Investors should review this press release for a comprehensive understanding of the company's performance and its forward-looking statements. The company has provided financial information on both a GAAP and non-GAAP basis, with management emphasizing that the non-GAAP figures are used for internal operational and planning purposes and are intended to supplement, not replace, GAAP financial statements. A reconciliation between GAAP and non-GAAP measures is available within the press release, which is crucial for investors seeking to understand the nuances of Gilead's financial reporting and make informed investment decisions.

Key Highlights

1Gilead Sciences announced its Q2 2022 financial results via an 8-K filing on August 2, 2022.
2The full financial details are presented in the press release filed as Exhibit 99.1.
3The company provided financial information using both GAAP and non-GAAP measures.
4Management utilizes non-GAAP information for internal operational, budgeting, and financial planning.
5Investors are advised to consider non-GAAP information as supplementary to GAAP financial statements.
6A reconciliation between GAAP and non-GAAP financial data is available in the press release.
7The information provided in this 8-K and Exhibit 99.1 is not considered 'filed' for the purposes of Section 18 of the Exchange Act, nor incorporated by reference into other filings.

GILEAD SCIENCES, INC. 8-K Report, Financial Results (Aug 2, 2022)

Summary

Key Highlights

Frequently Asked Questions